Amlodipine + amlodipine / olmesartan medoxomil combination + Hydrochlorothiazide
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes, Hypertension
Trial Timeline
May 1, 2008 → Jun 1, 2009
NCT ID
NCT00654745About Amlodipine + amlodipine / olmesartan medoxomil combination + Hydrochlorothiazide
Amlodipine + amlodipine / olmesartan medoxomil combination + Hydrochlorothiazide is a approved stage product being developed by Daiichi Sankyo for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT00654745. Target conditions include Type 2 Diabetes, Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00654745 | Approved | Completed |
Competing Products
20 competing products in Type 2 Diabetes